These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7193277)

  • 1. Cis-platinum therapy of previously treated head and neck cancer: the Southwest Oncology Group's two-dose-per-month outpatient regimen.
    Panettiere FJ; Lehane D; Fletcher WS; Stephens R; Rivkin S; McCracken JD
    Med Pediatr Oncol; 1980; 8(3):221-5. PubMed ID: 7193277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of retinoic acid and cis-platinum for advanced squamous cell cancer of the head and neck based on experimental evidence of drug synergism.
    Weisman RA; Christen R; Los G; Jones V; Kerber C; Seagren S; Glassmeyer S; Orloff LA; Wong W; Kirmani S; Howell S
    Otolaryngol Head Neck Surg; 1998 May; 118(5):597-602. PubMed ID: 9591856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bleomycin and cis-platinum with or without mitomycin C in 110 previously untreated patients with head and neck cancer.
    Israel L; Aguilera J; Soudant J; Penot JC; Breau JL; Morere JF
    Am J Clin Oncol; 1983 Jun; 6(3):305-11. PubMed ID: 6189388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Ginsberg L; Lawhorn K; Hong WK; Lippman SM
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-33-S19-37. PubMed ID: 9427263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
    Vokes EE; Moormeier JA; Ratain MJ; Egorin MJ; Haraf DJ; Mick R; Weichselbaum RR
    Cancer Chemother Pharmacol; 1992; 29(3):178-84. PubMed ID: 1733549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
    Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH;
    Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical phase I study of paclitaxel followed by cisplatin in advanced head and neck squamous cell carcinoma.
    Hanauske AR; Schilling T; Heinrich B; Kau R; Herzog M; Quasthoff S; Bochtler H; Diergarten K; Rastetter J
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):35-9. PubMed ID: 8553082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck.
    Kohno N; Kitahara S; Tamura E; Tanabe T; Nakanoboh M; Kawada M; Shirasaka T
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():592-9. PubMed ID: 10895216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer.
    Vokes EE; Schilsky RL; Weichselbaum RR; Guaspari A; Guarnieri CM; Whaling SM; Panje WR
    Cancer; 1989 Mar; 63(6 Suppl):1048-53. PubMed ID: 2783881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.
    Shin DM; Glisson BS; Khuri FR; Ginsberg L; Papadimitrakopoulou V; Lee JJ; Lawhorn K; Gillenwater AM; Ang KK; Clayman GL; Callender DL; Hong WK; Lippman SM
    J Clin Oncol; 1998 Apr; 16(4):1325-30. PubMed ID: 9552033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University Study.
    Al-Sarraf M; Metch B; Kish J; Ensley J; Rinehart JJ; Schuller DE; Coltman CA
    Cancer Treat Rep; 1987; 71(7-8):723-6. PubMed ID: 3300967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ifosfamide, cisplatin, and 13-Cis retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck: a phase I-II study.
    Recchia F; Lalli A; Lombardo M; De Filippis S; Saggio G; Fabbri F; Rosselli M; Capomolla E; Rea S
    Cancer; 2001 Aug; 92(4):814-21. PubMed ID: 11550152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of weekly high-dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck.
    Planting AS; de Mulder PH; de Graeff A; Verweij J
    Eur J Cancer; 1997 Jan; 33(1):61-5. PubMed ID: 9071901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: a preliminary report.
    Hussain M; Salwen W; Kucuk O; Ensley J
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-43-S19-45. PubMed ID: 9427265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer.
    Guntinas-Lichius O; Appenrodt S; Veelken F; Krug B
    Laryngoscope; 2006 Apr; 116(4):613-8. PubMed ID: 16585868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study.
    Hussain M; Benedetti J; Smith RE; Rodriguez GI; Schuller D; Ensley J
    Cancer; 1995 Oct; 76(7):1233-7. PubMed ID: 8630903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
    Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
    BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma.
    Kim HS; Kim HR; Kim GM; Kim HS; Koh YW; Kim SH; Choi EC; Hong YK; Sung JH; Kim SM; Kim JH; Cho BC
    Cancer Chemother Pharmacol; 2012 Oct; 70(4):539-46. PubMed ID: 22868340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Gedlicka C; Formanek M; Selzer E; Burian M; Kornfehl J; Fiebiger W; Cartellieri M; Marks B; Kornek GV
    Oncology; 2002; 63(2):145-50. PubMed ID: 12239449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.